5.5 C
Sunday, December 5, 2021

Coronavirus, ok by the US authority to test the Italian DiaSorin

- Advertisement -spot_imgspot_img
- Advertisement -spot_imgspot_img


DiaSorin Molecular, a division of the Italian DiaSorin group listed on the Milan stock exchange, has received authorization from the US Food and Drug Administration for emergency use for the Simplexa COVID-19 Direct Kit test, which «is able to provide an answer rapid and simple for the detection of acute respiratory syndrome caused by Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, directly from nasopharyngeal swabs ». This is an important first step to do as many tests as possible in order to free those who are not at risk by allowing economic activities to be restarted.

Many private diagnostic laboratories would already be equipped to cover thousands of tests per week. But the indications of the Ministry of Health, contained in a circular, prepare the swab only for symptomatic cases that require hospitalization. The cost varies from 60 to 100 euros per analysis carried out, including the cost of suitably equipped staff. General practitioners could do it too, but materials, resources and above all time are lacking.

The government currently has confidence only from ministry accredited laboratories, one per region or almost. They allow you to avoid incurring false negatives and false positives. Some regions, see Emilia Romagna, are gearing up with drive-trough, car testing, but experts do not agree on their complete reliability. The new diagnostic test of the Italian Diasorin is ready at this point to go on the market by reducing the process to one hour only compared to the current seven. But it will only be delivered to hospital laboratories.

«From the indications given by the company the presentation of the test the FDA was expected by the end of March 2020. – Equita analysts point out – We recall that our 2020 estimates incorporate 20 million positive impact margins from the Covid-19 test while we estimate that the reduction of the volumes of routine tests involves a negative impact of 40 million in terms of revenues “. The pharmaceutical group has accelerated the times: a prospect rewarded for some time by the stock exchange that since the end of February the title has gained 22%.

. Tags News i : test (t) detection (t) syndrome (t) buffer (t) Simplexa COVID-19 Direct Kit (t) DiaSorin (t) coronavirus


- Advertisement -spot_imgspot_img
Latest news
- Advertisement -spot_img
Related news
- Advertisement -spot_img


Please enter your comment!
Please enter your name here